DOCSLIB.ORG

Caspase-3 Cleaves XIAP in a Positive Feedback Loop to Sensitize Melanoma Cells to TRAIL-Induced Apoptosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Caspase-3 Cleaves XIAP in a Positive Feedback Loop to Sensitize Melanoma Cells to TRAIL-Induced Apoptosis Oncogene (2011) 30, 575–587 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc ORIGINAL ARTICLE Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis MHo¨rnle1, N Peters1, B Thayaparasingham1,HVo¨rsmann1, H Kashkar2 and D Kulms1 1Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Baden-Wu¨rttemberg, Germany and 2Institute for Medical Microbiology, Immunology and Hygiene, Center of Molecular Medicine Cologne, University of Cologne, Cologne, Germany Successful treatment of melanoma is still challenging, 57 kDa protein which appears to be ubiquitously because metastasis remain chemoresistant and radio- expressed in adult and fetal tissues (Hunter et al., resistant. Accordingly, combinational treatments invol- 2007). XIAP consists of three BIR domains (baculoviral ving death ligands are mandatory. In a recent study from IAP repeat 1–3), a RING-finger domain conferring our lab, the majority out of 18 melanoma cell lines ubiquitin (Ub) protein ligase (E3) activity and a recently remained resistant against treatment with the death ligand discovered evolutionarily conserved Ub-acceptor (UBA) TRAIL (tumor necrosis factor related apoptosis inducing domain (Gyrd-Hansen et al., 2008; Srinivasula and ligand). Resistance was shown to be mainly due to Ashwell, 2008). XIAP was identified as the only cellular incomplete processing of caspase-3 into catalytically protein being able to bind caspase-3, -7 and -9 directly inactive p21 by binding of the anti-apoptotic protein and to inhibit both the initiation and the execution X-linked inhibitor of apoptosis protein (XIAP). Co- phase of apoptosis (Deveraux et al., 1999). Given its role irradiation with sub-lethal ultraviolet (UV) B caused in apoptosis and its frequently elevated expression in depletion of XIAP resulting in synergistic sensitization of malignant cells, XIAP has been considered as a all but two melanoma cell lines to TRAIL. We show here promising therapeutic target in mammalian cancer. the XIAP depletion to essentially require initial caspase- Consequently, research efforts have lately been focused mediated cleavage, which promotes proteasomal degrada- on the development of drugs targeting XIAP (IAP tion of XIAP. Utilizing specific caspase inhibitors and inhibitors), which are currently being evaluated in small interfering RNA-mediated knockdown, we further clinical trials (Schimmer et al., 2006). identified caspase-3 to be responsible for performing the Pro-apoptotic second mitochondria-derived activator initial cleavage of XIAP after UVB treatment. Additional of caspase/direct inhibitor of apoptosis-binding protein evidence suggests an accelerated mitochondrial outer with low pI (Smac/DIABLO), being released from membrane permeabilization in response to co-treatment mitochondria during the onset of intrinsic apoptosis, is with TRAIL and UVB, which directs the release of XIAP known to functionally inhibit XIAP by distracting the antagonizing factors including Smac. Distraction of XIAP protein from caspases (Du et al., 2000; Sun et al., 2008). consequently liberates caspase-3 to autocatalytically Full autocatalytic processing of released caspases con- process into active p17. Activated caspase-3 cleaves XIAP sequently executes the apoptotic process, while the fate and further enhances its activation in a positive regulatory of XIAP is still discussed. Smac/DIABLO-dependent feedback loop. The molecular mechanism discovered here and -independent mechanisms have been described to appears to have broader implications, because cleavage of mediate ubiquitination and proteasomal degradation of XIAP was also shown to accompany cisplatin-induced XIAP thereby enhancing apoptosis (Fu et al., 2003; sensitization of melanoma cells to TRAIL. Yang and Du, 2004; Sohn et al., 2006; Liu et al., 2007; Oncogene (2011) 30, 575–587; doi:10.1038/onc.2010.434; Galban and Duckett, 2009). Vice versa, there are published online 20 September 2010 numerous reports implying E3 activity of XIAP to cause ubiquitination and immediate proteasomal degradation Keywords: caspase-3; XIAP; melanoma; apoptosis of pro-apoptotic XIAP counterparts, including cytosolic Smac/DIABLO (MacFarlane et al., 2002; Morizane et al., 2005; Rehm et al., 2006), caspase-9 (Morizane Introduction et al., 2005), caspase-7 (Creagh et al.,2004)andcaspase-3 (Suzuki et al.,2001;Chenet al., 2003), thereby directing The most intensively studied inhibitor of apoptosis them to proteasomal degradation. Taken together, the protein (IAP) family member, XIAP (X-linked IAP), is a cellular decision between pro- and anti-apoptotic re- sponses underlies the regulation of caspase activity mainly provided by a multilayered cross-talk between Correspondence: Dr D Kulms, Institute of Cell Biology and XIAP and caspases and intracellular regulator circuits Immunology, University of Stuttgart, Allmandring 31, Stuttgart, including mitochondria and proteasomes. Baden-Wu¨rttemberg 70569, Germany. E-mail: [email protected] Malignant melanoma represents one of the most Received 15 April 2010; revised 4 August 2010; accepted 16 August 2010; aggressive malignancies with a highly chemoresistant published online 20 September 2010 and radioresistant metastatic stage (Flaherty, 2006), XIAP cleavage by caspase-3 sensitizes melanoma to TRAIL MHo¨rnle et al 576 offering a poor prognosis for affected patients active p17 fragment (Figure 1b). To inquire whether (Lasithiotakis et al., 2006). Therefore, therapeutic XIAP depletion during apoptosis induction is dependent strategies combining chemotherapeutic drugs and tumor on proteasomal degradation, cells were treated with the selective death ligands are under investigation to proteasome inhibitor MG132 before TRAIL þ UVB improve cancer treatment (Ganten et al., 2006; Zhang stimulation. Strikingly, proteasomal inhibition regained et al., 2006; Koschny et al., 2007). An effective offence only a truncated 29 kDa form of XIAP, whereas no to malignant melanoma with the tumor selective ligand accumulation of the full-length protein could be TRAIL (tumor necrosis-related apoptosis inducing detected. This suggests proteolytic processing of XIAP ligand; Walczak et al., 1999) is curtailed by the fact to be responsible for generation of the 29 kDa XIAP that many melanoma cell lines are a priori resistant fragment, which is subsequently committed to protea- against TRAIL-induced apoptosis (Zeise et al., 2004). somal degradation (Figure 1c). This assumption was On investigating 18 melanoma cell lines, we could supported by the observation that apoptosis induc- recently show that TRAIL susceptibility was completely tion—as documented by poly (ADP-ribose) polymerase independent of the tumor progression stage, while only cleavage—clearly coincided with decrease in wt-XIAP, the minority of cell lines responded to TRAIL at all but with accumulation of the c-terminal cleavage (Thayaparasingham et al., 2009). Co-exposure to a non- product D1-241-XIAP in cells ectopically expressing apoptotic UV (ultraviolet) B dose was shown to highly both variants and treated with the proteasome inhibitor synergistically sensitize all melanoma cell lines to MG132 (Figure 1d). Of note, in primary melanocytes, TRAIL-induced apoptosis, providing an excellent tool XIAP depletion did not occur when using identical to study the mechanism underlying TRAIL resistance. TRAIL þ UVB doses and even remained absent when TRAIL insensitivity was based on incomplete caspase-3 treating these primary cells with a high dose of 500 ng/ processing into the catalytic inactive p21 fragment only, ml TRAIL and 400 J/m2 UVB (Figure 1c), proposing a while UVB-induced sensitization coincided with XIAP tumorselective mechanism. depletion, completion of caspase-3 activation yielding Based on biochemical cell-free analyses, caspases have the catalytically active p17, and consequently apoptosis been previously shown to be capable of cleaving XIAP induction (Thayaparasingham et al., 2009). Investigat- and the data provided identified a specific caspase- ing TRAIL resistance of melanoma cells and their cleavage motive in XIAP (Deveraux et al., 1999). synergistic sensitization by sub-lethal UVB, we revealed Accordingly, the contribution of caspases in XIAP a novel mechanism involving caspase-3-induced clea- processing was exemplarily investigated using the vage of XIAP as a prerequisite for its proteasomal melanoma cell line WM-115 (vertical growth phase). degradation. Our data elucidate the nodal point causing Application of pan caspase inhibitors (Q-Val-Asp(non- TRAIL resistance in melanoma and may consequently omethylated)-OPhMe)inhibitor (QVD); z-Val-Ala-Asp help to open new doors for tumorselective killing. (OMe)-FMK (zVAD)) completely prevented depletion of XIAP upon TRAIL þ UVB treatment and also circumvented stabilization of truncated XIAP upon Results concomitant proteasome inhibition (Figure 2a). Using specific inhibitors for caspase-6 (z-Val-Glu-Ile-Asp(OMe)- Caspase-mediated proteolytic cleavage of XIAP promotes FMK, (zVEID)), -8 (z-Ile-Glu-Thr-Asp(OMe)-FMK its proteasomal degradation and sensitization of (zIETD)), -3 (z-Asp-Glu-Val-Asp(OMe)-FMK, (zDEVD)) melanoma cells to TRAIL and -9 (z-Leu-Glu-His-Asp(OMe)-FMK, (zLEHD)), ana- Resistance of melanoma cells to TRAIL-induced lysis of XIAP depletion revealed that any of the tested apoptosis has been shown to be independent of the caspases could potentially be involved in XIAP processing, tumor progression stage
Load more

Recommended publications
  • XIAP's Profile in Human Cancer
    biomolecules Review XIAP’s Profile in Human Cancer Huailu Tu and Max Costa * Department of Environmental Medicine, Grossman School of Medicine, New York University, New York, NY 10010, USA; [email protected] * Correspondence: [email protected] Received: 16 September 2020; Accepted: 25 October 2020; Published: 29 October 2020 Abstract: XIAP, the X-linked inhibitor of apoptosis protein, regulates cell death signaling pathways through binding and inhibiting caspases. Mounting experimental research associated with XIAP has shown it to be a master regulator of cell death not only in apoptosis, but also in autophagy and necroptosis. As a vital decider on cell survival, XIAP is involved in the regulation of cancer initiation, promotion and progression. XIAP up-regulation occurs in many human diseases, resulting in a series of undesired effects such as raising the cellular tolerance to genetic lesions, inflammation and cytotoxicity. Hence, anti-tumor drugs targeting XIAP have become an important focus for cancer therapy research. RNA–XIAP interaction is a focus, which has enriched the general profile of XIAP regulation in human cancer. In this review, the basic functions of XIAP, its regulatory role in cancer, anti-XIAP drugs and recent findings about RNA–XIAP interactions are discussed. Keywords: XIAP; apoptosis; cancer; therapeutics; non-coding RNA 1. Introduction X-linked inhibitor of apoptosis protein (XIAP), also known as inhibitor of apoptosis protein 3 (IAP3), baculoviral IAP repeat-containing protein 4 (BIRC4), and human IAPs like protein (hILP), belongs to IAP family which was discovered in insect baculovirus [1]. Eight different IAPs have been isolated from human tissues: NAIP (BIRC1), BIRC2 (cIAP1), BIRC3 (cIAP2), XIAP (BIRC4), BIRC5 (survivin), BIRC6 (apollon), BIRC7 (livin) and BIRC8 [2].
    [Show full text]
  • Type of the Paper (Article
    Supplementary Material A Proteomics Study on the Mechanism of Nutmeg-induced Hepatotoxicity Wei Xia 1, †, Zhipeng Cao 1, †, Xiaoyu Zhang 1 and Lina Gao 1,* 1 School of Forensic Medicine, China Medical University, Shenyang 110122, P. R. China; lessen- [email protected] (W.X.); [email protected] (Z.C.); [email protected] (X.Z.) † The authors contributed equally to this work. * Correspondence: [email protected] Figure S1. Table S1. Peptide fraction separation liquid chromatography elution gradient table. Time (min) Flow rate (mL/min) Mobile phase A (%) Mobile phase B (%) 0 1 97 3 10 1 95 5 30 1 80 20 48 1 60 40 50 1 50 50 53 1 30 70 54 1 0 100 1 Table 2. Liquid chromatography elution gradient table. Time (min) Flow rate (nL/min) Mobile phase A (%) Mobile phase B (%) 0 600 94 6 2 600 83 17 82 600 60 40 84 600 50 50 85 600 45 55 90 600 0 100 Table S3. The analysis parameter of Proteome Discoverer 2.2. Item Value Type of Quantification Reporter Quantification (TMT) Enzyme Trypsin Max.Missed Cleavage Sites 2 Precursor Mass Tolerance 10 ppm Fragment Mass Tolerance 0.02 Da Dynamic Modification Oxidation/+15.995 Da (M) and TMT /+229.163 Da (K,Y) N-Terminal Modification Acetyl/+42.011 Da (N-Terminal) and TMT /+229.163 Da (N-Terminal) Static Modification Carbamidomethyl/+57.021 Da (C) 2 Table S4. The DEPs between the low-dose group and the control group. Protein Gene Fold Change P value Trend mRNA H2-K1 0.380 0.010 down Glutamine synthetase 0.426 0.022 down Annexin Anxa6 0.447 0.032 down mRNA H2-D1 0.467 0.002 down Ribokinase Rbks 0.487 0.000
    [Show full text]
  • Supplementary Information Method CLEAR-CLIP. Mouse Keratinocytes
    Supplementary Information Method CLEAR-CLIP. Mouse keratinocytes of the designated genotype were maintained in E-low calcium medium. Inducible cells were treated with 3 ug/ml final concentration doxycycline for 24 hours before performing CLEAR-CLIP. One 15cm dish of confluent cells was used per sample. Cells were washed once with cold PBS. 10mls of cold PBS was then added and cells were irradiated with 300mJ/cm2 UVC (254nM wavelength). Cells were then scraped from the plates in cold PBS and pelleted by centrifugation at 1,000g for 2 minutes. Pellets were frozen at -80oC until needed. Cells were then lysed on ice with occasional vortexing in 1ml of lysis buffer (50mM Tris-HCl pH 7.4, 100mM NaCl, 1mM MgCl2, 0.1 mM CaCl2, 1% NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS) containing 1X protease inhibitors (Roche #88665) and RNaseOUT (Invitrogen #10777019) at 4ul/ml final concentration. Next, TurboDNase (Invitrogen #AM2238, 10U), RNase A (0.13ug) and RNase T1 (0.13U) were added and samples were incubated at 37oC for 5 minutes with occasional mixing. Samples were immediately placed on ice and then centrifuged at 16,160g at 4oC for 20 minutes to clear lysate. 25ul of Protein-G Dynabeads (Invitrogen #10004D) were used per IP. Dynabeads were pre-washed with lysis buffer and pre- incubated with 3ul of Wako Anti-Mouse-Ago2 (2D4) antibody. The dynabead/antibody mixture was added to the lysate and rocked for 2 hours at 4oC. All steps after the IP were done on bead until samples were loaded into the polyacrylamide gel.
    [Show full text]
  • The Autism Protein Ube3a/E6AP Remodels Neuronal Dendritic Arborization Via Caspase-Dependent Microtubule Destabilization
    The Journal of Neuroscience, January 10, 2018 • 38(2):363–378 • 363 Neurobiology of Disease The Autism Protein Ube3A/E6AP Remodels Neuronal Dendritic Arborization via Caspase-Dependent Microtubule Destabilization Natasha Khatri,1,2 James P. Gilbert,1 Yuda Huo,1 Roozhin Sharaflari,1 Michael Nee,1 Hui Qiao,1 and XHeng-Ye Man1,2 1Department of Biology, Boston University, Boston, Massachusetts 02215, and 2Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts 02118 UBE3A gene copy number variation and the resulting overexpression of the protein E6AP is directly linked to autism spectrum disorders (ASDs).However,theunderlyingcellularandmolecularneurobiologyremainslessclear.HerewereporttheroleofASD-relatedincreased dosage of Ube3A/E6AP in dendritic arborization during brain development. We show that increased E6AP expression in primary cul- tured neurons leads to a reduction in dendritic branch number and length. The E6AP-dependent remodeling of dendritic arborization results from retraction of dendrites by thinning and fragmentation at the tips of dendrite branches, leading to shortening or removal of dendrites. This remodeling effect is mediated by the ubiquitination and degradation of XIAP (X-linked inhibitors of aptosis protein) by E6AP, which leads to activation of caspase-3 and cleavage of microtubules. In vivo, male and female Ube3A 2X ASD mice show decreased XIAP levels, increased caspase-3 activation, and elevated levels of tubulin cleavage. Consistently, dendritic branching and spine density are reduced in cortical neurons of Ube3A 2X ASD mice. In revealing an important role for Ube3A/E6AP in ASD-related developmental alteration in dendritic arborization and synapse formation, our findings provide new insights into the pathogenesis of Ube3A/E6AP- dependent ASD.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Targeting the Ubiquitin System in Glioblastoma', Frontiers in Oncology
    Citation for published version: Licchesi, J 2020, 'Targeting the Ubiquitin System in Glioblastoma', Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.574011 DOI: 10.3389/fonc.2020.574011 Publication date: 2020 Document Version Publisher's PDF, also known as Version of record Link to publication University of Bath Alternative formats If you require this document in an alternative format, please contact: [email protected] General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 24. Sep. 2021 REVIEW published: 25 November 2020 doi: 10.3389/fonc.2020.574011 Targeting the Ubiquitin System in Glioblastoma Nico Scholz 1, Kathreena M. Kurian 2, Florian A. Siebzehnrubl 3 and Julien D. F. Licchesi 1* 1 Department of Biology & Biochemistry, University of Bath, Bath, United Kingdom, 2 Brain Tumour Research Group, Institute of Clinical Neurosciences, University of Bristol, Bristol, United Kingdom, 3 Cardiff University School of Biosciences, European Cancer Stem Cell Research Institute, Cardiff, United Kingdom Glioblastoma is the most common primary brain tumor in adults with poor overall outcome and 5-year survival of less than 5%. Treatment has not changed much in the last decade or so, with surgical resection and radio/chemotherapy being the main options.
    [Show full text]
  • Regulation of Apoptosis by XIAP Ubiquitin- Ligase Activity Andrew James Schile
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2009 Regulation of Apoptosis by XIAP Ubiquitin- Ligase Activity Andrew James Schile Follow this and additional works at: http://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons Recommended Citation Schile, Andrew James, "Regulation of Apoptosis by XIAP Ubiquitin- Ligase Activity" (2009). Student Theses and Dissertations. Paper 125. This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact [email protected]. REGULATION OF APOPTOSIS BY XIAP UBIQUITIN-LIGASE ACTIVITY A Thesis Presented to the Faculty of The Rockefeller University In Partial Fulfillment of the Requirements for The degree of Doctor of Philosophy by Andrew James Schile June 2009 © Copyright by Andrew James Schile 2009 REGULATION OF APOPTOSIS BY XIAP UBIQUITIN-LIGASE ACTIVITY Andrew James Schile, Ph.D. The Rockefeller University 2009 Virtually all animal cells have the known ability to self-destruct by undergoing apoptosis, a morphologically distinct form of programmed cell death. The proper regulation of apoptosis is critical for both development and tissue homeostasis, and inhibition of apoptosis contributes to the development and progression of cancer. Inhibitor of Apoptosis Proteins (IAPs) can bind to and inhibit caspases, the key executioners of apoptosis. Because IAPs are frequently over-expressed in human tumors, they have become major pharmacological targets for developing new cancer therapeutics. Many IAPs contain RING domains that function as E3 ubiquitin-ligases to regulate the abundance of IAPs themselves and their binding partners by engaging the ubiquitin system.
    [Show full text]
  • New Insights Into the Cellular Temporal Response to Proteostatic Stress
    TOOLS AND RESOURCES New insights into the cellular temporal response to proteostatic stress Justin Rendleman1†, Zhe Cheng1†, Shuvadeep Maity1†, Nicolai Kastelic2, Mathias Munschauer2, Kristina Allgoewer1, Guoshou Teo1, Yun Bin Matteo Zhang1, Amy Lei1, Brian Parker1, Markus Landthaler2,3, Lindsay Freeberg4, Scott Kuersten4, Hyungwon Choi5,6, Christine Vogel1* 1Center for Genomics and Systems Biology, Department of Biology, New York University, New York, United States; 2Berlin Institute for Medical Systems Biology, Max Delbru¨ ck Center for Molecular Medicine, Berlin, Germany; 3Integrative Research Institute for the Life Sciences, Institute of Biology, Humboldt University, Berlin, Germany; 4Illumina Inc, Madison, United States; 5National University of Singapore, Singapore; 6Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore Abstract Maintaining a healthy proteome involves all layers of gene expression regulation. By quantifying temporal changes of the transcriptome, translatome, proteome, and RNA-protein interactome in cervical cancer cells, we systematically characterize the molecular landscape in response to proteostatic challenges. We identify shared and specific responses to misfolded proteins and to oxidative stress, two conditions that are tightly linked. We reveal new aspects of the unfolded protein response, including many genes that escape global translation shutdown. A subset of these genes supports rerouting of energy production in the mitochondria. We also find that many genes change at multiple levels, in either the same or opposing directions, and at different time points. We highlight a variety of putative regulatory pathways, including the stress- dependent alternative splicing of aminoacyl-tRNA synthetases, and protein-RNA binding within the 3’ untranslated region of molecular chaperones. These results illustrate the potential of this information-rich resource.
    [Show full text]
  • Whole Transcriptomic Expression Differences in EBV Immortalized Versus Primary B-Cells
    W&M ScholarWorks Undergraduate Honors Theses Theses, Dissertations, & Master Projects 12-2010 Whole Transcriptomic Expression Differences in EBV Immortalized versus Primary B-Cells Dolores Huberts College of William and Mary Follow this and additional works at: https://scholarworks.wm.edu/honorstheses Part of the Biology Commons Recommended Citation Huberts, Dolores, "Whole Transcriptomic Expression Differences in EBV Immortalized versus Primary B- Cells" (2010). Undergraduate Honors Theses. Paper 347. https://scholarworks.wm.edu/honorstheses/347 This Honors Thesis is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Undergraduate Honors Theses by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. Whole Transcriptomic Expression Differences in EBV Immortalized versus Primary B-Cells A thesis submitted in partial fulfillment of the requirement for the degree of Bachelor of Science with Honors in Biology from the College of William and Mary in Virginia By Dolores Huberts Accepted for Honors ________________________________________ Lizabeth A. Allison, Director ________________________________________ Matthew Wawersik ________________________________________ Drew LaMar ________________________________________ Beverly Sher Williamsburg, Virginia December 17, 2010 ABSTRACT The Epstein–Barr Virus (EBV) is a human gamma herpes virus that infects more than 90% of the human population worldwide. It is commonly known in the US as the cause of Infectious Mononucleosis, and around the world as the cause of nasopharyngeal carcinoma and malignant lymphomas such as non-Hodgkin lymphoma, endemic Burkett’s lymphoma and Hodgkin lymphoma. Additionally, the EBV is used to immortalize cells to create cell lines for in-vitro studies.
    [Show full text]
  • High Expression of XIAP and Bcl-2 May Inhibit Programmed Cell Death
    https://doi.org/10.1590/0004-282X20170156 ARTICLE High expression of XIAP and Bcl-2 may inhibit programmed cell death in glioblastomas Alta expressão de XIAP e Bcl-2 pode inibir morte celular programada em glioblastomas Daniela Pretti da Cunha Tirapelli1, Isis Lacrose Lustosa1, Sarah Bomfim Menezes1, Indira Maynart Franco1, 1 2 3 Andressa Romualdo Rodrigues , Fernanda Maris Peria , Alexandre Magno da Nóbrega Marinho , Luciano Neder Serafini4, Carlos Gilberto Carlotti Jr1, Luís Fernando Tirapelli1 ABSTRACT Glioblastoma (GBM) is the most malignant glioma and represents 29% of all brain tumors. Tumorigenesis is intimately connected with characteristics acquired in the physiologic pathway of cellular death. Objective: In the present study, the expression of anti-apoptotic (XIAP and Bcl-2) and apoptotic (cytochrome C, caspase 9, APAF-1), caspase 3 and the Smac/DIABLO genes related to the apoptosis pathway were evaluated in 30 samples of glioblastoma. Methods: The gene expression was evaluated in 30 glioblastomas (WHO grade IV) and compared to 10 white matter control samples with real-time PCR. Results and Conclusion: There were higher expressions of XIAP (p = 0.0032) and Bcl-2 (p = 0.0351) in the glioblastoma samples compared to the control samples of normal brain. These results raise the question of whether Bcl-2 and XIAP genes can be responsible for the inhibition of programmed cell death in glioblastomas. Moreover, they provide additional information capable of allowing the development of new target therapy strategies. Keywords: glioblastoma; apoptosis; X-linked inhibitor of apoptosis protein; B-cell lymphoma 2. RESUMO O glioblastoma (GBM) é o glioma mais maligno e representa 29% de todos os tumores cerebrais.
    [Show full text]
  • Caspase-9 and Apaf-1 Are Expressed and Functionally Active in Human Neuroblastoma Tumor Cell Lines with 1P36 LOH and Ampli®Ed MYCN
    Oncogene (2002) 21, 1848 ± 1858 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and ampli®ed MYCN Tal Teitz1,3, Tie Wei1,2,3, Dong Liu1, Virginia Valentine1, Marcus Valentine1, Jose Grenet1, Jill M Lahti1 and Vincent J Kidd*,1 1Department of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, TN 38105, USA Important roles have been suggested for caspase-8, Introduction caspase-9 and Apaf-1 in controlling tumor development and their sensitivity to chemotherapeutic agents. Methy- Neuroblastoma is one of the most common pediatric lation and deletion of Apaf-1 and CASP8 results in the solid tumors, and it is commonly classi®ed by the stage loss of their expression in melanoma and neuroblastoma, of tumor development (Brodeur et al., 1992). Early respectively, while CASP9 localization to 1p36.1 stage neuroblastoma tumors (i.e., stages I, II and III) suggests it is a good candidate tumor suppressor. The are readily treatable with chemotherapeutic drugs and status of CASP9 and Apaf-1 expression in numerous irradiation, and many will even spontaneously regress. neuroblastoma cell lines with/without ampli®ed MYCN However, the prognosis for late stage tumors, es- and chromosome 1p36 loss-of-heterozygosity (LOH) was pecially stage IV tumors, and stage IV tumors that therefore examined to test the hypothesis that one or overexpress the oncoprotein N-Myc due to ampli®ca- both of these genes are tumor suppressors in neuro- tion of the corresponding MYCN gene, is not favorable blastoma.
    [Show full text]
  • Caspase-9 Cleavage, Do You Need It ?
    COMMENTARY Caspase-9 cleavage, do you need it ? Davina Twiddy and Kelvin Cain†, MRC Toxicology Unit, Hodgkin Building, University of Leicester, Lancaster Rd, LE1 9HN Caspase-9 which is activated by association with the Apaf-1 apoptosome complex cleaves and activates the downstream effector caspases-3 and -7, thereby executing the caspase-cascade and cell death programme. Although, caspase-9 does not need to be cleaved to be active, apoptotic cell death is always accompanied by autocatalytic cleavage and by further downstream effector caspase-dependent cleavage of caspase-9. In this issue of the Biochemical Journal, Denault and co-workers evaluate the role of caspase-3-dependent cleavage of caspase-9 and conclude that this mechanism mainly serves to enhance apoptosis by alleviating XIAP inhibition of the apical caspase. Key words: caspase-9, caspase-3, Apaf-1 apoptosome, XIAP (X-linked inhibitor of apoptosis), Smac (Second mitochondrial activator of caspases). ACTIVATING THE CASPASE CASCADE AND THE ROLE OF XIAP Caspases are present in healthy cells as zymogens, which are usually activated by proteolytic cleavage of an interlinker peptide sequence that allows rearrangement of peptide loops to form a fully functional active site. Caspases-3 and -7 are the apical effector caspases and are activated, by either caspase-9 or caspase-8. The inappropriate activation of this essentially irreversible caspase cascade requires an independent and tightly regulated failsafe mechanism. To this end, the cell has evolved altogether different mechanisms for activating the initiator caspases which are responsible for cleaving and activating procaspases-3 and -7. In the case of the intrinsic pathway which can be triggered by chemical or radiation-induced damage, the execution phase of cell death involves an efflux of cytochrome c from the mitochondria, which binds to and † Corresponding author ;[email protected] activates Apaf-1 (apoptotic protease-activating factor-1).
    [Show full text]